A prospective, randomized, double‐blind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC ‐3197) and adalimumab (Humira) in patients with rheumatoid arthritis-Reference-Cited by-同舟云学术

A prospective, randomized, double‐blind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC ‐3197) and adalimumab (Humira) in patients with rheumatoid arthritis

Published:2015-07-14 Issue:11 Volume:19 Page:1157-1168
ISSN:1756-1841
Container-title:International Journal of Rheumatic Diseases
language:en
Short-container-title:Int J Rheum Dis

Author:

Jani Rajendrakumar H.¹,Gupta Rajiv²,Bhatia Girish³,Rathi Gaurav⁴,Ashok Kumar Patnala⁵,Sharma Reena⁶,Kumar Uma⁷,Gauri Liyakat A.⁸,Jadhav Praveen⁹,Bartakke Girishchandra¹⁰,Haridas Vikram¹¹,Jain Dinesh¹²,Mendiratta Sanjeev K.¹

Affiliation:

1. Clinical R & D Cadila Healthcare Limited The Zydus Group Ahmedabad India

2. Malpani Multispecialty Hospital Jaipur India

3. Medipoint Hospital Pvt. Ltd. Pune India

4. Rathi Orthopaedic and Research Centre Ahmedabad India

5. Department of Orthopedics Unit‐2 King George Hospital Visakhapatnam India

6. Shalby Hospital Ahmedabad India

7. Clinical Immunology and Rheumatology Service AIIMS New Delhi India

8. SP Medical College & Associated Group of Hospitals Bikaner India

9. Omkar Heart Institute & Nursing Home & Rheumatology Clinic Nasik India

10. B J Medical College and Sassoon General Hospital Pune India

11. Sushruta Multispecialty Hospital and Research Centre Pvt. Ltd. Vidyanagar, Hubli India